![]() |
市場調查報告書
商品編碼
1439257
全球乾粉吸入器市場:洞察、競爭格局、市場預測:2030 年Dry Powder Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2023年全球乾粉吸入器市場規模為139.35億美元。 預計到 2030 年,該市場將達到 186.26 億美元,2024 年至 2030 年的預測期內複合年增長率為 4.58%。 乾粉吸入器市場受到COVID-19 盛行率上升、糖尿病盛行率上升、氣喘盛行率上升、囊性纖維化病例激增、慢性阻塞性肺病(COPD) 等多種因素的推動,該市場已顯示出正成長。癌症盛行率急劇上升、老年人口增加、產品技術進步的增加。
乾粉吸入器市場的主要驅動因素之一是糖尿病盛行率的上升。 乾粉吸入器用於使用胰島素粉末治療糖尿病。 因此,糖尿病患者數量的增加預計將增加對乾粉吸入器的需求,並在預測期內(2024-2030年)推動整個乾粉吸入器市場向前發展。
此外,推動乾粉吸入器市場成長的另一個重要因素是氣喘盛行率的上升。 例如,根據世界衛生組織 (WHO) 2023 年發布的數據,2019 年氣喘影響了全球 2.62 億人。 此外,氣喘盛行率的上升將增加對乾粉吸入器的需求,因為乾粉吸入器用於將氣喘治療藥物輸送到肺部,導致預測期內對乾粉吸入器市場的需求增加。突然增加。
本報告調查了全球乾粉吸入器市場,包括市場概述、按產品類型、患者類型、應用、類型、地區以及進入市場的公司概況劃分的趨勢。我們提供
Dry Powder Inhaler Devices Market By Product Type (Disposable, Capsule, And Blister), By Patient Type (Adult And Pedriatric), By Application (Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others), By Type (Single-Use And Multi-Use), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of covid-19 and rising prevalence of diabetes
The global dry powder inhaler devices market was valued at USD 13,935 million in 2023, growing at a CAGR of 4.58% during the forecast period from 2024 to 2030 to reach USD 18,626 million by 2030. The dry powder inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the market for dry powder inhaler devices is estimated to grow during the forecast period from 2024 to 2030.
Dry Powder Inhaler Devices Market Dynamics:
One of the main drivers of the dry powder inhaler devices market is the rising prevalence of diabetes. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes affected roughly 537 million people of age between 20-79 years. By the year 2030, the overall number of diabetes is expected to reach 643 million, and by 2045, it will reach 783 million. Thus, dry powder inhaler are used to treat diabetes by using insulin powder. Therefore, rising diabetes cases increases the demand of dry powder inhaler devices, which drives the overall dry powder inhaler devices market forward over the forecast period (2024-2030).
Moreover, another key factor which is responsible for the growth of dry powder inhaler devices market is the increasing prevalence of asthma. For instance, according to World Health Organization (WHO) published data in the year 2023, asthma affected 262 million people in 2019 worldwide. Further, dry powder inhaler devices are used to deliver asthma medication to the lungs, thus increasing prevalence of asthma increases the demand for dry powder inhaler devices, which leads to a surge in the dry powder inhaler devices market during the forecast period.
However, lack of awareness about dry powder inhaler devices and disadvantages associated with the devices, can hamper the global dry powder inhaler devices market growth.
The COVID-19 pandemic has positively impacted the market for dry powder inhaler devices, this can be anticipated owing to the severe effects of COVID-19 on lungs and COVID-19 patients that had suffered with respiratory infections as an after effect of COVID-19, as well as shortness of breath as its prevalent symptom, had also contributed to the dry powder inhaler devices demand among COVID-19 patients. Hence, the demand for dry powder inhaler devices will continue to rise in the forecast period from 2024-2030.
Dry Powder Inhaler Devices Market Segment Analysis:
Dry Powder Inhaler Devices Market by Product Type (Disposable, Capsule and Blister), Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, COVID-19, Diabetes, and Others), Type (Single-Use and Multi-Use), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).
In the by type segment of dry powder inhaler devices market, single use is expected to share a significant revenue in the year 2023. Single use dry powder inhalers devices are disposable, cost effective, minimize the risk of infections, offers a better approach to deliver medications than reusable ones and can assist a variety of needs. Thus, these benefits associated with the single use dry powder inhaler devices increases its demand, which leads to a surge in the dry powder inhaler devices overall market. However, increase in patents approvals associated with the dry powder inhaler devices also drives its market growth.
In February 2020, Hovione Technology, a Contract Development and Manufacturing Company, has reported that one of its big dosage dry powder inhaler (DPI) systems, the TwinMax DPI, has received patent approvals. TwinMax is a 2-puff disposable DPI that is developed for applications that need a high dosage administration to the lungs. It has a patent-pending architecture that allows it to deliver dosages up to 100 mg as medication alone or tailored particles.
Furthermore, such type of approvals and benefits associated with single-use dry powder inhaler devices, in the product type segment would result in the rising demand for dry powder inhaler devices which in turn would provide a conducive growth for the overall dry powder inhaler devices market during the forecast 2024-2030.
North America is expected to dominate the overall Dry Powder Inhaler Devices Market:
Among all the regions, North America is expected to dominate the global dry powder inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the rising prevalence of COVID-19 and surge in cystic fibrosis cases are expected to increase the demand of dry powder inhaler devices in the North American market.
According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increased the respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increased the demand for dry powder inhaler devices, which surged the growth for dry powder inhaler devices overall market forecast.
Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per cystic fibrosis Canada's 2020 annual data report from the Canadian Cystic Fibrosis Registry, had released that in 2020, there were 4,332 Canadians with CF, with 62 percent of them being adults. Further, dry powder inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for dry powder inhaler devices, which boost the dry powder inhaler devices overall market growth.
Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in dry powder inhaler devices market.
Dry Powder Inhaler Devices Market Key Players:
Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Hofliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS, and among others.
Recent Developmental Activities in the Dry Powder Inhaler Devices:
In June 2022, Glenmark Pharmaceuticals Ltd, a research-driven global integrated pharmaceutical company, is one of the first to introduce a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) in the United Kingdom under the brand name Tiogiva® for the treatment of chronic obstructive pulmonary disease (COPD).
In May 2020, Iconovo, offers the development of inhalation products, has announced that the ICOcapTM dry powder inhaler, which is based on capsules, has received CE approval for use in clinical studies.
Key Takeaways from the Dry Powder Inhaler Devices Market Report Study
Target Audience who can be benefited from this Dry Powder Inhaler Devices Market Report Study
Frequently Asked Questions for Dry Powder Inhaler Devices:
A Dry-Powder Inhaler (DPI) is a device that uses dry powder to deliver medicine to the lungs. DPIs are often used to treat respiratory disorders such as asthma, bronchitis, emphysema, and COPD, but they have also been used to treat diabetes mellitus.
The global dry powder inhaler devices market was valued at USD 13,935 million in 2023, growing at a CAGR of 4.58% during the forecast period from 2024 to 2030 to reach USD 18,626 million by 2030.
The dry powder inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.
Some of the key market players operating in the Dry powder inhaler devices market include Boehringer Ingelheim Inc, CHIESI Farmaceutici S.p.A, Cipla Inc, GSK Group of Companies, Hovione, OPKO Health Inc, Teva Pharmaceutical Industries Ltd, Vectura Group Ltd, Radius Innovation & Development, Otsuka Pharmaceutical Co Ltd, RESPIRA THERAPEUTICS INC, MannKind Corporation, Pharmaxis Ltd, Stevanato Group, Harro Hofliger Verpackungsmaschinen GmbH, H&T Presspart Manufacturing Ltd, Catalent Inc, Merxin Ltd, Manta Devices LLC, PUREIMS and among others.
North America is expected to dominate the global Dry powder inhaler devices market. Factors contributing to the growth of dry powder inhaler devices market in the North America region are rising prevalence of COVID-19 and surge in cystic fibrosis cases.